Skip to content
AI in Healthcare

Article

Epic vs Oracle Health in 2026 — how the two big EHRs are actually shipping AI

Epic Cosmos, embedded copilots, and the App Orchard on one side; Oracle Fusion Analytics, the Clinical AI Agent, and a slower rebuild on the other. What each vendor is actually delivering in 2026.

By AI in Healthcare Editorial Updated
  • epic
  • oracle-health
  • health-system
  • copilot
  • governance
  • enterprise
  • clinical-ai
  • operations

Every conversation about AI in a U.S. health system eventually comes back to the same question: what is our EHR vendor giving us, and what are we going to have to build (or buy) around it? In 2026 the answer depends heavily on which of the two dominant vendors your organization runs. Epic and Oracle Health cover the overwhelming majority of large-hospital seats between them, and the divergence in how each has approached embedded AI is now wide enough that it shapes procurement strategy, IT staffing plans, and the shape of the third-party vendor market itself.

This piece walks through what each vendor is actually shipping in 2026 — not what the marketing decks promise, but what a CMIO on a Monday morning can point at inside the product. The two companies are running very different plays. Understanding the difference matters if you are procuring AI tools, negotiating an EHR contract, or trying to predict which third-party vendors will still be around in three years.

Epic in 2026 — the “embedded copilot everywhere” strategy

Epic’s approach is best described as distributed embedding: rather than one flagship AI product, the vendor has pushed generative and predictive features into dozens of surfaces across the chart. The In Basket message drafter, the Note Buddy summarizer, the Chart Search generative response, the Sepsis Model, the deterioration index, the coding-assistance panel — none of them individually is the “Epic AI product.” Together, they are.

The Cosmos dataset — Epic’s federated repository of de-identified records drawn from participating health systems, now covering more than 288 million patients according to Epic’s own July 2025 figures — is the substrate that powers the more analytically ambitious features and, increasingly, the research work coming out of health-system data-science teams. Cosmos-derived comparisons (“patients like this one”) now appear in-line in the chart at some participating organizations, and Epic Research publishes a steady stream of cohort studies drawn from the same dataset. That gives Epic something Oracle does not currently have at comparable scale: a first-party, EHR-native denominator against which model outputs can be benchmarked.

The other Epic play worth naming is the App Orchard / Showroom / Vendor Services channel. Third-party AI vendors that want to sell into an Epic customer base overwhelmingly integrate through that channel. Ambient-scribe vendors, imaging-workflow companies, patient-messaging tools, and inbox-triage products all typically ship an Epic-integrated flavor first. That has two consequences: it lowers integration cost for Epic customers relative to Oracle customers, and it gives Epic quiet veto power over which third-party AI categories flourish.

Notable in-product AI surfaces in 2026:

  • In Basket message drafter (patient-message replies). Widely deployed. Positioned around clinician time-savings, not diagnostic accuracy. Suggested-response drafts appear as editable text a clinician signs.
  • Note Buddy / chart summarization. Generative summaries of long histories, medication lists, or hospital-course narratives. Deployment varies by organization; governance conservatism is the main gating factor.
  • Coding assistance. Integrated with the Problem List and encounter documentation flows; contributed to the coding-density conversation now dominating payer trend reports (see the PwC 2027 medical-cost-trend commentary).
  • Predictive analytics library. Deterioration index, sepsis model, no-show predictor — pre-AI-boom models that live in the same operational tooling and are now being repositioned as “clinical AI.”
  • Cosmos-powered comparators. “Patients like this” panels drawn from the federated dataset; rolled out to a subset of Cosmos participants.

The Epic play is fewer decisions, more surfaces. A health system that runs Epic gets a lot of AI without ever writing an AI vendor check. It also gets a lot of AI without a lot of surface control. Turning individual features on or off, versioning them, or exempting a service line from a specific model is a chart-configuration question, not a vendor-selection question.

Oracle Health in 2026 — the “rebuild the platform, ship a headline copilot” strategy

Oracle Health (the entity formerly known as Cerner) is running a different play, forced in part by the operational realities of the post-acquisition rebuild. The multi-year VA Millennium modernization effort has consumed a large fraction of Oracle Health’s platform-engineering attention, and the AI investment has been concentrated rather than distributed.

The flagship product is the Oracle Clinical AI Agent — a voice-driven documentation and workflow assistant that Oracle first previewed at HIMSS 2024 and has been rolling into general availability since. Positioned as the direct competitor to Epic’s ambient-scribe partners and to Nuance DAX Copilot, the Clinical AI Agent is a first-party ambient-plus-agentic tool, not a partner integration. Oracle’s product page for the Clinical AI Agent describes voice-driven note generation, order entry, and specialty-specific workflows; the general availability rollout has been gated by site-by-site enablement rather than a mass release.

The second Oracle bet is Oracle Fusion Analytics for Healthcare — the cross-application analytics layer that pulls from the EHR, ERP, and revenue-cycle products under a single semantic model. Fusion Analytics is Oracle’s answer to the “Cosmos problem” — the recognition that a health system running Oracle Health also runs Oracle ERP and Oracle HCM, and that the analytic and AI story is stronger when the vendor can span all three. In practice, Fusion Analytics is the layer where Oracle’s AI value proposition to CFOs and COOs (not CMIOs) is actually being made in 2026.

Notable in-product AI surfaces in 2026:

  • Clinical AI Agent. Voice-driven documentation, order entry, in-visit assistance. First-party. Site-by-site enablement. Direct competitor to Epic’s ambient-scribe partnerships.
  • Oracle Health Marketplace / Cerner Open Developer Experience. Third-party integration exists but is thinner than Epic’s App Orchard. Ambient-scribe vendors selling into Oracle customers have historically had to invest more per integration.
  • Predictive-analytics library. Deterioration and sepsis models exist and are used, though with less public benchmarking visibility than Epic’s equivalents.
  • Fusion Analytics for Healthcare. Cross-application AI-assisted reporting, with predictive and generative features being layered in progressively.

The Oracle play is fewer surfaces, more control. A health system running Oracle Health gets less breadth of in-product AI than an Epic peer, but often more strategic room to bring in third-party vendors and to make architecture choices that are not implicitly pre-decided by the EHR vendor.

Where the two diverge in practice

Three axes matter for procurement teams weighing what to build, buy, or wait for.

1. Ambient scribes. On Epic, the ambient-scribe question is a partner-selection exercise: which of DAX, Abridge, Suki, and the health-system-built alternatives fits best inside Epic’s integration surface. On Oracle Health, the ambient-scribe question increasingly includes “or the Clinical AI Agent” as a first-party option. That changes the total-cost-of-ownership math and, for organizations that value single-vendor accountability, may tip the decision.

2. Analytics and research. Epic Cosmos has no direct Oracle equivalent at comparable scale. A health system that leans on federated cohort research as part of its clinical-AI evaluation program has more infrastructure available on Epic than on Oracle. The offset is that Oracle Fusion Analytics offers cross-domain (clinical + financial + operational) analytics that Cosmos does not natively span.

3. Third-party vendor ecosystems. Ambient-scribe, imaging-workflow, and patient-messaging vendors overwhelmingly ship Epic-integrated versions before Oracle-integrated ones. That gap has narrowed since 2024 but remains real. For organizations relying on a specific third-party AI vendor, EHR choice is not neutral.

What the governance program has to do

Whichever EHR you run, the health-system governance program has to keep up. Some concrete implications:

  • Inventory your embedded AI. If you run Epic, you already have more embedded AI than most governance charters realize. The In Basket drafter, the Note Buddy summarizer, and the Cosmos comparator are all clinical AI under any reasonable definition. Your inventory should list them by name and by version.
  • Understand the update pathway. Epic’s release train and Oracle’s release train have different cadences, different customer-communication practices, and different mechanisms for opting out of individual features. Governance-program leaders should know both. The FDA’s PCCP framework governs any of these features that meet the SaMD threshold.
  • Track the Joint Commission RUAIH reporting scope. If your organization is pursuing RUAIH certification, both embedded EHR AI and third-party AI count. Vendors are getting better at giving you the artifacts (model cards, monitoring dashboards); ask.
  • Watch the coding-density conversation. Both vendors’ documentation-assistance features contribute to the coding-density signal payers are now naming as a cost-trend inflator. Contracting language will follow. Your revenue-cycle team should be at the AI governance table.

What we are watching next

  • Cosmos-vs-Fusion parity. Will Oracle stand up a Cosmos-scale federated clinical dataset? The commercial pressure to do so is growing, but the customer-consent infrastructure is not trivial.
  • First-party ambient scribes on Epic. Epic has publicly resisted becoming an ambient-scribe vendor, preferring the partner ecosystem. That posture is under real competitive pressure from Oracle’s Clinical AI Agent play. Watch for movement.
  • Foundation-model provenance. Which foundation model each vendor’s generative features rest on, whether it is frozen, and how updates are governed — see the FDA’s 2026 PCCP guidance update — is the least-transparent part of both vendors’ 2026 posture. Ask your account team.

Sources cited